logo
Hospital visits for Marijuana use linked to 72% higher dementia risk, major study warns

Hospital visits for Marijuana use linked to 72% higher dementia risk, major study warns

Time of India22-04-2025
Marijuana's potential medicinal benefits have shifted public perception of the psychoactive drug derived from the Cannabis plant, contributing to its growing popularity. Countries like Canada, Uruguay, Mexico and Thailand, and 22 states in the US have legalized recreational marijuana, while 50 countries have approved it for medicinal purposes.
However, one cannot ignore that its regular use has been associated with a heightened risk of a range of life-threatening conditions like strokes, heart attacks, cardiac arrhythmias, heart failure and myocarditis.
4/20 day, celebrated every year on April 20, by weed lovers, brought the drug into the spotlight, sparking discussions on its growing popularity as well as risks.
A
new study
published in the journal JAMA Neurology that links an increased risk of dementia to cannabis use is especially crucial in this regard. The terms cannabis and marijuana are often used interchangeably, but they are not exactly the same. While cannabis refers to the plant Cannabis sativa, marijuana is one of the products derived from this plant that has a high concentration of THC, the psychoactive cannabinoid.
Dementia and Marijuana connection
The connection between long-term cannabis and dementia isn't new and has been demonstrated in the previous studies. An American Journal of Psychiatry
study
discusses how cannabis use over a long period of time is linked to hippocampal atrophy and poorer cognitive function in midlife, which are known risk factors for dementia.
The new study delves into the five-year cognitive impact of cannabis-related medical emergencies, revealing a significant association between such events and an elevated risk of developing dementia.
'Someone who has an emergency room visit or hospitalization due to cannabis has a 23% increased risk of dementia within five years compared to someone who was at the hospital for another reason. They have a 72% greater risk compared to the general population,' says study coauthor Dr Daniel Myran, an assistant professor in the department of family medicine at the University of Ottawa in Canada.
'Those numbers have already factored out other reasons for dementia, such as age, sex, mental health or substance use, and whether or not you have chronic conditions such as diabetes or heart disease,' Myran added.
Earlier research shows marijuana users are nearly 25% more likely to need emergency care and hospitalization than nonusers.
'However, this is not a study that anyone should look at and say, 'Jury's in, and cannabis use causes dementia,'' Myran said. 'This is a study that brings up a concerning association that fits within a growing body of research.'
While medical marijuana is considered to be safe in limited doses under expert supervision, it is more complicated than that. Many people with
cannabis use disorder
are not able to stop using it and that's where the real problem lies.
US federal law doesn't allow the use of marijuana. However, many states allow medical use to treat pain, nausea and other symptoms. The THC in marijuana affects the brain, mood, behavior and thoughts, the reason why it is called psychoactive. Medicinal marijuana can be advised for conditions like Alzheimer's disease, HIV/AIDS, Amyotrophic lateral sclerosis (ALS), Epilepsy, and serious nausea or vomiting caused by cancer treatment. However, are its side effects worth it? Let's understand.
What's cannabis use disorder?
Cannabis Use Disorder (CUD), a medically recognized condition is marked by a problematic and often compulsive pattern of marijuana use. Its severity can vary from mild habits that interfere with daily life to full-blown addiction. Marijuana is part of cannabis, but not all cannabis is marijuana. Cannabis use disorder mainly involves THC-containing substances such as marijuana. Addiction to marijuana could happen when the brain's reward system takes over and amplifies compulsive marijuana-seeking.
People with cannabis use disorder are unable to stop using even though they encounter health or social problems from use, Dr. Robert Page II, a professor of clinical pharmacy and physical medicine at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora told CNN.
'When they stop using it, they either have withdrawal symptoms or have very bad mental health symptoms,' he added. 'They might have quite severe depression, or they might have anxiety, all of which can send them to the hospital.'
According to the CDC, around 30% of people can get addicted to marijuana. This can pose risk of attention, memory and learning problems, as per CDC.
What you need to know about marijuana's safety
'The other takeaway from this study is that many people believe marijuana to be natural and therefore safe,' Page said. 'It is a psychotropic medication, so it's going to have psychotropic effects. If you have underlying psychiatric issues, realize that you need to be transparent with your provider and let them know if you're using this medically or recreationally.'
According to mayoclinic, the other side effects of medical marijuana include increased heart rate, dizziness, problems with thinking and memory, slower reaction times, increased risk of heart attack and stroke, panic attacks, and hallucinations, among others.
Rastafari community of Antigua gain sacramental rights to marijuana
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Low cancer rate in A.P. prompts govt. to go for another exclusive survey
Low cancer rate in A.P. prompts govt. to go for another exclusive survey

The Hindu

time6 hours ago

  • The Hindu

Low cancer rate in A.P. prompts govt. to go for another exclusive survey

Following the NCD Survey-3 that was taken up across the State to assess prevalence of non-communicable diseases (NCD), including cancer, diabetes, and BP among the people of the State, Minister for Health, Medical Education and Family Welfare Satya Kumar Yadav has announced that another survey, NCD-4, would be taken up from September focussing only on cancer. While a cancer survey is already being conducted in the State as part of the NCD-3 from November 2024, the results showed that cancer prevalence is too low in Andhra Pradesh. He said cancer is the fourth leading cause of death in the country, and felt the reasons for low prevalence in A.P. have to be properly examined through another survey. Speaking at a three-day workshop being held for health staff for the NCD-4 survey in Mangalagiri on July 24, Thursday, Mr. Satya Kumar Yadav said while as part of the ongoing survey, the State government had set a target of screening 4.10 crore people, so far, 70% of the target has been completed. Around 3 crore people have been screened for three types of cancer: oral, breast and cervical. Around 2.90 crore people have been screened for oral cancer, and 2 crore for breast and cervical cancers, the Minister said, adding the results showed that only 0.35% of the screened people were diagnosed with one of these cancers. The number is low when compared to the cancer incidence in the country, he added. The Minister said the results could be due to lack of awareness among people about cancer or due to 'lack of skills' among the health staff, or due to lengthy questionnaires or misconceptions among people. Lack of coordination among field-level workers and 'lack of supervision by senior health workers' could also be the reasons. While the NCD-3 survey has not brought out the desired results, it cannot be said that it has failed. It is commendable that the survey was carried out for 3 crore people despite challenges. The survey has given the department an understanding of its own strengths and weak points that can be addressed in the NCD survey 4. Having lost his mother and a sibling to cancer, the Minister said he is aware of the consequences of cancer, and expressed concern that around 75,000 new cancer cases are reported in the State every year and 30,000 people die annually. He said the NCD-4 survey would begin after the ongoing survey ends in August.

Apollo, Siemens collaborate to advance liver healthcare with AI innovation
Apollo, Siemens collaborate to advance liver healthcare with AI innovation

Business Standard

timea day ago

  • Business Standard

Apollo, Siemens collaborate to advance liver healthcare with AI innovation

Apollo Hospitals and Siemens Healthineers on Wednesday announced a research collaboration founded on a shared ambition to advance innovations in artificial intelligence (AI) and imaging technologies, with the goal of improving lives. The research, spanning quantitative ultrasound imaging to AI-driven clinical solutions, aims to enhance liver disease management by improving patient care pathways and outcomes—from early detection and risk stratification to monitoring intervention and therapy response. The partnership combines technical and clinical expertise to develop innovative healthcare solutions for the growing burden of liver diseases in India, with a focus on early diagnosis, accurate detection, and precise monitoring to improve patient outcomes. As per Government of India guidelines, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), referred to as NAFLD in the report, is a growing cause of liver disease in India. Its prevalence ranges from 9 per cent to 32 per cent and is higher among individuals who are overweight, obese, or have diabetes. According to NFHS-4 (2015–2016), 18–20 per cent of adults are overweight or obese and 3–8 per cent have abnormal blood sugar levels. MASLD significantly increases cardiovascular risk, with heart disease being the leading cause of death. 'At Apollo, we believe that the future of healthcare lies at the intersection of clinical excellence and cutting-edge technology anchored in patient centricity. Our collaboration with Siemens Healthineers is a transformative step in using AI to redefine non-invasive diagnostics for liver disease. Due to diagnostic challenges and the evolving understanding of the disease, the true prevalence of MASLD may be underestimated. This poses a significant public health challenge, requiring increased awareness, early detection, and effective management strategies,' said Sangita Reddy, joint managing director, Apollo Hospitals. 'AI-driven disease progression models will play a pivotal role in the early detection of fibrosis, allowing timely interventions, cost-effective screening, and improved patient outcomes. These models will also facilitate precision population health strategies and clinical decision support across care settings. This partnership reflects Apollo's pioneering vision to embed intelligent systems across the clinical spectrum that enable faster, more accurate diagnoses and proactive patient management,' she added. 'Liver disease is a growing health concern in India. It's crucial to prioritise early diagnosis and prevention through advanced diagnostic tools, lifestyle changes, and increased awareness to reverse this trend. We believe that advanced technologies will aid timely and precise diagnosis, leading to better disease management and improved quality of life for patients. Our joint effort will help address the unmet needs in liver disease diagnosis and treatment, and we look forward to a fruitful partnership,' said Hariharan Subramanian, managing director, Siemens Healthcare. Following the 2024 memorandum of understanding, the Master Research Agreement (MRA) was formalised in March 2025, establishing a foundation for collaborative research in diagnostic and interventional ultrasound imaging. The signing ceremony for the MRA addendum was held on July 23, 2025, in Hyderabad, marking a significant milestone in this partnership.

Godavari Biorefineries gets Chinese patent for cancer molecule
Godavari Biorefineries gets Chinese patent for cancer molecule

Fibre2Fashion

timea day ago

  • Fibre2Fashion

Godavari Biorefineries gets Chinese patent for cancer molecule

Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB), through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office for its novel anti-cancer molecule - HYDROXY-1,4-NAPHTHALENEDIONE. This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. 'Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,' said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. 'This Chinese patent reinforces the promise of our lead molecule and the vital work being done by our team at Sathgen Therapeutics to develop innovative therapies for some of the most pressing medical needs worldwide.' Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its focus in translational research that addresses some of the world's most urgent health challenges. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Godavari Biorefineries' biotech arm, Sathgen Therapeutics, has secured a Chinese patent for its anti-cancer molecule Hydroxy-1,4-Naphthalenedione. The compound shows strong in vitro efficacy against cancer and cancer stem cells. GBL continues to expand globally, focusing on innovative cancer and antiviral therapies through advanced translational research. ALCHEMPro News Desk (HU)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store